Biocon Biologics, Viatris get USFDA nod for first interchangeable biosimilar Semglee for diabetes Ruchika Sharma29 July 2021 1:33 PM ISTThe interchangeable Semglee product, which will allow substitution of Semglee for the reference product, Lantus, at the pharmacy counter, will be...
Biocon net profit declines 23 percent at Rs 195 crore in Q2 Ruchika Sharma25 Oct 2020 9:45 AM ISTNew Delhi: Biotechnology major Biocon on Friday reported a 23.01 per cent fall in its consolidated net profit to Rs 195.4 crore for the second quarter...
Semglee now available for better blood sugar control in diabetes Dr Satabdi Saha3 Sept 2020 4:56 PM ISTSemglee (Insulin glargine) injection a long-acting human insulin analogue is now available in US to improve blood sugar control in adults and...
Biocon, Mylan get USFDA approval for insulin glargine injection Semglee Ruchika Sharma12 Jun 2020 1:17 PM ISTSemglee has an identical amino acid sequence to Sanofi's Lantus® and is approved for the same indications
